IL101683A0 - Method and assay system for neurotrophin activity - Google Patents

Method and assay system for neurotrophin activity

Info

Publication number
IL101683A0
IL101683A0 IL101683A IL10168392A IL101683A0 IL 101683 A0 IL101683 A0 IL 101683A0 IL 101683 A IL101683 A IL 101683A IL 10168392 A IL10168392 A IL 10168392A IL 101683 A0 IL101683 A0 IL 101683A0
Authority
IL
Israel
Prior art keywords
assay system
neurotrophin activity
neurotrophin
activity
assay
Prior art date
Application number
IL101683A
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL101683A0 publication Critical patent/IL101683A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/142Toxicological screening, e.g. expression profiles which identify toxicity
IL101683A 1991-07-03 1992-04-23 Method and assay system for neurotrophin activity IL101683A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72878491A 1991-07-03 1991-07-03
US76267591A 1991-09-20 1991-09-20

Publications (1)

Publication Number Publication Date
IL101683A0 true IL101683A0 (en) 1992-12-30

Family

ID=27111743

Family Applications (1)

Application Number Title Priority Date Filing Date
IL101683A IL101683A0 (en) 1991-07-03 1992-04-23 Method and assay system for neurotrophin activity

Country Status (9)

Country Link
EP (1) EP0593663A4 (en)
JP (1) JPH06509333A (en)
AU (1) AU2322392A (en)
CA (1) CA2112799A1 (en)
IE (1) IE921315A1 (en)
IL (1) IL101683A0 (en)
NZ (1) NZ242467A (en)
PT (1) PT100424A (en)
WO (1) WO1993000909A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025683A1 (en) * 1992-06-12 1993-12-23 Massachusetts Institute Of Technology A gene which prevents programmed cell death
US6902732B2 (en) 1992-06-12 2005-06-07 Massachusetts Institute Of Technology Identification and characterization of a gene which protects cells from programmed cell death and uses therefor
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
WO1994027982A1 (en) * 1993-05-28 1994-12-08 Cephalon, Inc. Use of indolocarbazole derivatives to treat a pathological condition of the prostate
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
US5602309A (en) * 1993-10-04 1997-02-11 University Of Kentucky Research Foundation Transgenic mice which overexpress nerve growth factor
WO1995022331A1 (en) * 1994-02-18 1995-08-24 Cephalon, Inc. Aqueous indolocarbazole solutions
JPH11509193A (en) * 1995-06-27 1999-08-17 ヘンリー エム.ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディシン A method for dynamically delaying cell cycle dynamics to enhance cell injury
US6274576B1 (en) 1995-06-27 2001-08-14 The Henry Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
US5859311A (en) * 1995-11-27 1999-01-12 University Of Kentucky Research Foundation Transgenic mice which overexpress neurotrophin-3 (NT-3) and methods of use
US7795246B2 (en) * 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
CA2524883C (en) 2003-05-16 2014-07-22 Universite Laval Potassium-chloride cotransporter kcc2 modulation for treatment of pain
JP2007537167A (en) 2004-05-14 2007-12-20 ユニヴェルシテ ラヴァル Regulation of phospholipase C gamma and thereby regulation of pain and nociception
EP2294183B1 (en) 2008-06-18 2015-12-16 The Texas A&M University System Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
WO2013138374A2 (en) * 2012-03-15 2013-09-19 Curna, Inc. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
US20150133529A1 (en) * 2012-05-16 2015-05-14 Rana Therapeutics, Inc. Compositions and methods for modulating bdnf expression

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor

Also Published As

Publication number Publication date
AU2322392A (en) 1993-02-11
EP0593663A1 (en) 1994-04-27
NZ242467A (en) 1995-06-27
WO1993000909A1 (en) 1993-01-21
IE921315A1 (en) 1993-01-13
CA2112799A1 (en) 1993-01-21
PT100424A (en) 1993-10-29
EP0593663A4 (en) 1996-10-30
JPH06509333A (en) 1994-10-20

Similar Documents

Publication Publication Date Title
GB2227981B (en) Active suspension system and method for controlling same
EP0586259A3 (en) Sign-language learning system and method
AU2864989A (en) Location system and method
EP0426393A3 (en) Instructing method and execution system
EP0766651A4 (en) Controlled denitrification process and system
AU2029592A (en) Fastening system and method
AU1875692A (en) Exhaust treatment system and method
EP0480726A3 (en) Pulse analysis system and method
IL101683A0 (en) Method and assay system for neurotrophin activity
LTIP1892A (en) Corrosian analysis system and method
EP0533196A3 (en) Version-up method and system
EP0549248A3 (en) An arbitration system and method
GB2236270B (en) System and apparatus for assembling workpieces
GB2206468B (en) Contention control system and method
GB2266167B (en) Communicating system and method for communicating data
GB2265718B (en) Assay apparatus and assay method
EP0435086A3 (en) Trailer anti-swing system and method
ZA922947B (en) Assay systems for neurotrophin activity
GB8906647D0 (en) An interaction support system and method
GB2273380B (en) Data processing system and data processing method using same
GB2273787B (en) Developing method and system
GB8906951D0 (en) Method and system for construction
GB9224401D0 (en) Turfing system and method
GB8918336D0 (en) Means and method for performing an activity
EP0802888A4 (en) Aeration system and method